Infliximab as an alternative treatment for Behçet disease when other therapies fail

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 2, 2008, Pages 212-215

  Ugras, Meltem ^a   Ertem, Deniz ^a   Celikel, Cigdem ^a   Pehlivanoglu, Ender ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCITONIN; COLCHICINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ANAMNESIS; ANAPHYLAXIS; ARTICLE; BEHCET DISEASE; BONE DENSITOMETRY; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; DRUG DOSE INCREASE; FAMILY HISTORY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPEREMIA; HYPOTENSION; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULARIZATION; VITAL SIGN;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CHILD; COLONOSCOPY; FEMALE; HUMANS; TREATMENT OUTCOME; ULCER;

EID: 38549089061     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181346b60     Document Type: Article

References (25)

1. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335:1078-1080.
2. Hassard VP, Binder SW, Nelson V, et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-9.
3. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol 2000;30:144-54.
4. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis alpha, interleukin (IL)6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-9.
5. Sfikakis PP, Theodossiasis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295.
6. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-1.
7. Haugeberg G, Velken M, Johnsen V. Succesful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 2004;63:744-5.
8. Travis SPL, Czajkowski M, McGovern DPB, et al. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-8.
9. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 2003;49:599-600.
10. Davtyan TK, Mkrtchyan NR, Manukyan HM, et al. Dexamethasone, colchicine and iodine-lithium-alpha-dextrin act differentially on the oxidative burst and endotoxin tolerance induction in vitro in patients with Behcet's disease. Int Immunopharmacol 2006;6:396-407.
11. Yazc H, Pazarl H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5.
12. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of mucocutaneous lesions of the Behçet's syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
13. Yasui K, Ohta K, Kobayashi M,et al. Successful treatment of Behçet's disease with pentoxifyline. Ann Intern Med 1996;124:891-3.
14. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine 2003;24:210-8.
15. Andreu M, Ramanoelina J, Fajnkuchen F, et al. Treatment of severe Behçet's disease with anti-TNF-alpha: infliximab: a case report. Ann Med Interne 2002;153:414-5.
16. Ridder L, Benninga MA, Taminiau JA, et al. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006;43:388-90.
17. Ridder L, Escher J, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistula in the Netherlands. J Pediatr Gastroentrol Nutr 2004;36:46-52.
18. Maxwell MJ, Muthu P, Pritty PE. Accidental colchicine overdose: a case report and literature review. Emerg Med J 2002;19:265-6.
19. Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 2004;3:47-56.
20. Schwartz LK, Kim MK, Coleman M, et al. Lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1030-4.
21. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
22. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7.
23. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
24. Hommes DW, Oldenburg B, van Bodegraven AA, et al. Guidelines for treatment with infliximab for Crohn's disease (Dutch Initiative on Crohn and Colitis). Neth J Med 2006;64:219-29.
25. Geborek P, Bladström A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.